Phone: 614/488-2118
Fax: 614/488-2647

1335 Dublin Rd., Suite 124A
Columbus, OH 43215

Protocol Categories

View All Protocols


Melanoma / Skin-Other

Alliance A091605
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
ECOG EA6134
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
NCCTG N0392
Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
SWOG S1320
A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NCS-763760) and Trametinib (NCS-763093) in BRAFV600E/K Mutant Melanoma
SWOG S1512
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
SWOG S1616
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
SWOG S1801
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma